Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

The FDA's Office of Prescription Drug Promotion issued Evolus a September warning letter over misleading Instagram promotions for Jeuveau, its prescription injectable prabotulinumtoxinA-xvfs. The regulatory action creates reputational and compliance risk for Evolus but does not indicate a product recall, sales restriction, or broader change to Jeuveau's approval status.